GoodRx (NASDAQ:GDRX) Upgraded at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of GoodRx (NASDAQ:GDRXFree Report) from a neutral rating to an overweight rating in a research note issued to investors on Friday, Marketbeat reports. The brokerage currently has $10.00 price target on the stock, up from their previous price target of $7.00.

Several other research analysts also recently commented on the company. Bank of America downgraded GoodRx from a buy rating to an underperform rating and decreased their price objective for the stock from $8.00 to $4.50 in a research note on Tuesday, January 2nd. Royal Bank of Canada raised their price objective on GoodRx from $5.00 to $7.00 and gave the stock a sector perform rating in a research note on Tuesday, January 16th. SVB Leerink initiated coverage on GoodRx in a research note on Monday, February 26th. They issued an outperform rating and a $8.00 price objective on the stock. Leerink Partnrs reaffirmed an outperform rating on shares of GoodRx in a research note on Monday, February 26th. Finally, Morgan Stanley decreased their target price on GoodRx from $8.00 to $5.50 and set an equal weight rating on the stock in a research note on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Hold and a consensus price target of $8.62.

Check Out Our Latest Stock Report on GoodRx

GoodRx Stock Down 3.2 %

NASDAQ GDRX opened at $8.08 on Friday. The stock’s 50-day moving average price is $6.45 and its 200-day moving average price is $6.00. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.85. GoodRx has a 52 week low of $4.14 and a 52 week high of $9.37. The company has a market capitalization of $3.28 billion, a P/E ratio of -404.00, a price-to-earnings-growth ratio of 7.70 and a beta of 1.43.

Hedge Funds Weigh In On GoodRx

Several institutional investors have recently added to or reduced their stakes in GDRX. Advisor Group Holdings Inc. grew its holdings in GoodRx by 17.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 28,454 shares of the company’s stock valued at $414,000 after buying an additional 4,265 shares in the last quarter. Raymond James & Associates boosted its holdings in shares of GoodRx by 24.0% in the 1st quarter. Raymond James & Associates now owns 13,806 shares of the company’s stock worth $267,000 after purchasing an additional 2,675 shares during the period. Citigroup Inc. boosted its holdings in shares of GoodRx by 107.6% in the 1st quarter. Citigroup Inc. now owns 41,084 shares of the company’s stock worth $794,000 after purchasing an additional 21,298 shares during the period. BlackRock Inc. boosted its holdings in shares of GoodRx by 5.8% in the 1st quarter. BlackRock Inc. now owns 1,110,156 shares of the company’s stock worth $21,459,000 after purchasing an additional 60,979 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in shares of GoodRx in the 1st quarter worth approximately $319,000. Hedge funds and other institutional investors own 33.63% of the company’s stock.

GoodRx Company Profile

(Get Free Report)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Further Reading

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.